Added to YB: 2025-12-30
Pitch date: 2025-12-26
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+0.3%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$36.6B
Pitch Price
$100.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.86
P/E
51.68
EV/Sales
3.07
Sector
Pharmaceuticals
Category
turnaround
Teva ($TEVA) - Knocking on the door of investment grade
TEVA (update): S&P upgraded to BB+ from BB, Moody's outlook positive. Leverage declined to 4.4x Q3, targeting sub-4.25x near-term, Moody's sees 3.5x in 12-18mo. Now 'Rising Star' candidate - one notch from BBB- investment grade would trigger passive fund buying. Risk: pharma volatility could halt branded portfolio growth needed for deleveraging.
Read full article (3 min)